Can TMO sustain its Q4 2024 EPS momentum?

**Thermo Fisher Scientific (TMO) is likely to sustain its Q4 2024 EPS momentum** based on several key factors:

1. **Consistent Growth Trajectory**: TMO has demonstrated a consistent growth trajectory in its EPS. While the latest report period showed a year-over-year growth of 13.57% in net income and a 13.81% increase in diluted EPS, the company has a history of surpassing EPS expectations, with an average surprise of 1.52% over the past four quarters.

|code|Ticker|Name|Date|Net Income YoY|Total Revenue YoY|Diluted EPS YoY|market_code|
|---|---|---|---|---|---|---|---|
|TMO|TMO.N|Thermo Fisher|2024 Q1|3.018575851393189|-3.408029878618114|4.216867469879522|169|
|TMO|TMO.N|Thermo Fisher|2024 Q2|14.023494860499266|-1.3661457845981098|15.099715099715109|169|
|TMO|TMO.N|Thermo Fisher|2024 Q3|-3.893805309734513|0.22697181766597316|-3.8461538461538445|169|
|TMO|TMO.N|Thermo Fisher|2024 Q4|13.57409713574097|4.675730295792762|13.80952380952381|169|

2. **Strategic Growth Initiatives**: TMO's focus on innovation and customer partnerships is likely to translate into continued EPS growth. The company has announced new product launches, such as the Iliad scanning transmission electron microscope, and has deepened strategic partnerships. These initiatives are expected to bolster its market position and drive future earnings growth.
3. **Financial Performance and Guidance**: TMO's financial performance in Q4 2024 was robust, with a net income of $1.82 billion and total revenue of $11.4 billion. The company has tightened its full-year adjusted EPS guidance to $21.35-$22.07, indicating confidence in sustaining its EPS momentum.

|code|Ticker|Name|Date|Net Income YoY|Net Income|market_code|
|---|---|---|---|---|---|---|
|TMO|TMO.N|Thermo Fisher|2024 Q1|3.018575851393189|1.331E9|169|
|TMO|TMO.N|Thermo Fisher|2024 Q2|14.023494860499266|1.553E9|169|
|TMO|TMO.N|Thermo Fisher|2024 Q3|-3.893805309734513|1.629E9|169|
|TMO|TMO.N|Thermo Fisher|2024 Q4|13.57409713574097|1.824E9|169|

|code|Ticker|Name|Date|Total Revenue YoY|Total Revenue|market_code|
|---|---|---|---|---|---|---|
|TMO|TMO.N|Thermo Fisher|2024 Q1|-3.408029878618114|1.0345E10|169|
|TMO|TMO.N|Thermo Fisher|2024 Q2|-1.3661457845981098|1.0541E10|169|
|TMO|TMO.N|Thermo Fisher|2024 Q3|0.22697181766597316|1.0598E10|169|
|TMO|TMO.N|Thermo Fisher|2024 Q4|4.675730295792762|1.1395E10|169|

|code|Ticker|Name|Date|Diluted EPS YoY|Diluted EPS|market_code|
|---|---|---|---|---|---|---|
|TMO|TMO.N|Thermo Fisher|2024 Q1|4.216867469879522|3.46|169|
|TMO|TMO.N|Thermo Fisher|2024 Q2|15.099715099715109|4.04|169|
|TMO|TMO.N|Thermo Fisher|2024 Q3|-3.8461538461538445|4.25|169|
|TMO|TMO.N|Thermo Fisher|2024 Q4|13.80952380952381|4.78|169|

4. **Market Position and Growth Prospects**: As a leading player in the Life Sciences Tools & Services industry, TMO is well-positioned to capitalize on emerging market trends, such as the growth in the diabetes care industry and the demand for tools supporting synthetic biology and personalized medicine. These growth opportunities are expected to support continued EPS growth.
5. **Analyst Confidence**: Analysts have a positive outlook on TMO, with a consensus rating of "Buy" and an average analyst price target of $657.13, indicating confidence in the company's future performance. This sentiment is reinforced by recent price target increases by TD Cowen and Jefferies.

In conclusion, TMO's strong financial performance, strategic growth initiatives, and positive analyst sentiment suggest that the company is well-positioned to sustain its Q4 2024 EPS momentum.